2 results
Approved WMOCompleted
Primary Objective:The primary objective of this study is to compare the efficacy of bimekizumab administered scfor 16 weeks versus secukinumab at achieving complete clearance (PASI100) in subjects withmoderate to severe chronic plaque PSO.The…
Approved WMOPending
To compare the objective response rate between patients with metastatic non-small cell lung cancer characterized by PDL-1 TPS<50% and low cTML (<300 nonsynonymous mutations) and either actionable mutation, inactivating STK11 or KEAP1…